ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 0259

Impact of Comorbidity on Disease Activity and Functional Status in Patients with Rheumatoid Arthritis Receiving Biologic DMARDs, a Longitudinal Analysis of the KOBIO-RA
Abstract Number: 0260

Impacts of Poor Prognostic Factors in Rheumatoid Arthritis on Clinical Outcomes and Treatment Choices from an Observational Cohort of Korean Patients with Rheumatoid Arthritis
Abstract Number: 0261

Machine Learning and Computational Pathology Can Reveal Synovial Pathotypes in Mice and Humans
Abstract Number: 0262

Predictors of Fragility Fracture Amongst Patients with Rheumatoid Arthritis: An Observational Cohort Study
Abstract Number: 0263

DAS28 (disease Activity Score) Elevations in Patients with Rheumatoid Arthritis (RA) Who Have Comorbid Fibromyalgia Are Explained by Elevated Tender Joint Counts as Much as by Elevated Patient Global Assessment
Abstract Number: 0264

Reasons for Early Discontinuation of Targeted Synthetic (ts) or Biologic (b) DMARDs; Chart Review of 20,343 Drug Episodes Given to Patients with Rheumatoid Arthritis
Abstract Number: 0265

In Patients with Rheumatoid Arthritis, Clinical Examination of the Feet Is Important for Understanding Individual Disease Burden, but Does Not Provoke a Change in Therapy in Most Cases
Abstract Number: 0266

Expression of Cytokine and Chemokine Genes in Patients with Clinically Suspect Arthralgia; A Longitudinal Study During Progression to Inflammatory Arthritis or Non-Progression
Abstract Number: 0267

Cancer Risk with Biologic and Targeted Synthetic DMARDs in Patients with Rheumatic Diseases and Previous Malignancy: Results from the BIOBADASER Register
Abstract Number: 0268

Risks of Mortality in Elderly-onset Rheumatoid Arthritis: Analysis from the TRA Clinical Electronic Registry
Abstract Number: 0269

Practical Cut-off Points for Using the Rheumatoid Arthritis Impact of Disease (RAID) Questionnaire in Remote Consult Triage
Abstract Number: 0270

Lower mRNA-anti SARS-Cov2 Induced IgG Antibody Responses to S1, S2 and RBD May Result from a Delayed IgA and IgM Class Switch in Patients with Rheumatoid Arthritis
Abstract Number: 0271

Temporal Trends and Risk of Rheumatoid Arthritis in Celiac Disease Patients: A Nationwide Population-based Study
Abstract Number: 0272

Long-Term Efficacy of Baricitinib in Patients with Rheumatoid Arthritis with Inadequate Response to Bdmards: Results from RA-BEYOND up to 6.9-Years of Treatment
Abstract Number: 0273

An Update on the Integrated Safety Analysis of Filgotinib in Patients with Moderately to Severely Active RA

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].